PL3334763T3 - Nowe przeciwciała anty-pd-1 - Google Patents
Nowe przeciwciała anty-pd-1Info
- Publication number
- PL3334763T3 PL3334763T3 PL16834675.7T PL16834675T PL3334763T3 PL 3334763 T3 PL3334763 T3 PL 3334763T3 PL 16834675 T PL16834675 T PL 16834675T PL 3334763 T3 PL3334763 T3 PL 3334763T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- novel anti
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/086594 WO2017024515A1 (en) | 2015-08-11 | 2015-08-11 | Novel anti-pd-1 antibodies |
| CN2016071374 | 2016-01-19 | ||
| PCT/CN2016/094624 WO2017025051A1 (en) | 2015-08-11 | 2016-08-11 | Novel anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3334763T3 true PL3334763T3 (pl) | 2024-12-02 |
Family
ID=57982964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16834675.7T PL3334763T3 (pl) | 2015-08-11 | 2016-08-11 | Nowe przeciwciała anty-pd-1 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11008391B2 (pl) |
| EP (2) | EP3334763B1 (pl) |
| JP (4) | JP6883579B2 (pl) |
| KR (1) | KR102055396B1 (pl) |
| AU (2) | AU2016305697B2 (pl) |
| CA (1) | CA2993276A1 (pl) |
| CL (1) | CL2018000370A1 (pl) |
| CO (1) | CO2018000992A2 (pl) |
| DK (1) | DK3334763T3 (pl) |
| EA (1) | EA201890468A1 (pl) |
| EC (1) | ECSP18018842A (pl) |
| ES (1) | ES2992478T3 (pl) |
| FI (1) | FI3334763T3 (pl) |
| HR (1) | HRP20241381T1 (pl) |
| HU (1) | HUE068751T2 (pl) |
| IL (3) | IL293385B1 (pl) |
| LT (1) | LT3334763T (pl) |
| MA (1) | MA42626A (pl) |
| MX (2) | MX392711B (pl) |
| MY (1) | MY187739A (pl) |
| PE (1) | PE20181018A1 (pl) |
| PH (1) | PH12018500183A1 (pl) |
| PL (1) | PL3334763T3 (pl) |
| PT (1) | PT3334763T (pl) |
| RU (2) | RU2020124273A (pl) |
| SA (2) | SA521422116B1 (pl) |
| SG (1) | SG10201914109VA (pl) |
| SI (1) | SI3334763T1 (pl) |
| UA (1) | UA124379C2 (pl) |
| WO (1) | WO2017025051A1 (pl) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7014706B2 (ja) | 2015-07-13 | 2022-02-01 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法 |
| UA124379C2 (uk) | 2015-08-11 | 2021-09-08 | Усі Байолоджікс Айрленд Лімітед | Нові антитіла проти білка pd-1 |
| CA2997963A1 (en) | 2015-09-29 | 2017-04-06 | Celgene Corporation | Pd-1 binding proteins and methods of use thereof |
| MA43260A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| CA3026474A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| MX2019002867A (es) | 2016-09-19 | 2019-11-12 | Celgene Corp | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. |
| RU2757316C2 (ru) | 2016-09-21 | 2021-10-13 | СиСТОНЕ ФАРМАСЬЮТИКАЛС | Новые моноклональные антитела к белку программируемой смерти 1(pd-1) |
| KR20240019398A (ko) | 2016-10-28 | 2024-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법 |
| CN110072890B (zh) | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| CN106939049B (zh) * | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| CN118356488A (zh) | 2017-05-30 | 2024-07-19 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| BR112019018759A2 (pt) | 2017-05-30 | 2020-05-05 | Bristol-Myers Squibb Company | composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico |
| PT3631454T (pt) | 2017-05-30 | 2023-11-23 | Bristol Myers Squibb Co | Tratamento de tumores positivos para lag-3 |
| JP7780857B2 (ja) | 2017-06-01 | 2025-12-05 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| IL271009B2 (en) | 2017-06-05 | 2025-10-01 | Janssen Biotech Inc | Antibodies that specifically bind PD-1 and methods of use |
| UY37829A (es) | 2017-08-03 | 2019-01-31 | Amgen Inc | Muteínas de interleucina 21 y métodos de tratamiento |
| EP3691643A4 (en) | 2017-09-29 | 2021-06-16 | Bristol-Myers Squibb Company | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| CA3081748A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| MA51631A (fr) | 2018-01-12 | 2020-11-18 | Amgen Inc | Anticorps anti-pd1 et méthodes de traitement |
| TWI802633B (zh) | 2018-01-15 | 2023-05-21 | 大陸商南京傳奇生物科技有限公司 | 針對pd-1之單域抗體及其變異體 |
| EP3740506A1 (en) | 2018-01-16 | 2020-11-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| US20210038559A1 (en) | 2018-01-22 | 2021-02-11 | Thomas Richard Gadek | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CA3088542A1 (en) | 2018-01-22 | 2019-07-25 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| US12152074B2 (en) * | 2018-03-22 | 2024-11-26 | CeingeBiotecnologie Avanzate Franco Salvatore Scarl | Antagonistic PD-1, PD-L1 and LAG-3 binding proteins |
| KR102761890B1 (ko) | 2018-03-23 | 2025-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | Mica 및/또는 micb에 대한 항체 및 그의 용도 |
| JP2021519771A (ja) | 2018-03-30 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍を処置する方法 |
| KR20200140315A (ko) | 2018-04-04 | 2020-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd27 항체 및 그의 용도 |
| CA3096705A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| CA3099547A1 (en) | 2018-05-07 | 2019-11-14 | Reshma Abdulla RANGWALA | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| CN120714025A (zh) | 2018-06-20 | 2025-09-30 | 因赛特公司 | 抗pd-1抗体及其用途 |
| MX2021000726A (es) | 2018-07-26 | 2021-03-25 | Bristol Myers Squibb Co | Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer. |
| WO2020057610A1 (en) * | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| CN112839962A (zh) | 2018-10-09 | 2021-05-25 | 百时美施贵宝公司 | 用于治疗癌症的抗mertk抗体 |
| HUE069062T2 (hu) | 2018-10-19 | 2025-02-28 | Bristol Myers Squibb Co | Kombinációs terápia melanomára |
| JP2022505647A (ja) | 2018-10-23 | 2022-01-14 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍の処置方法 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| MY205758A (en) | 2018-11-16 | 2024-11-12 | Bristol Myers Squibb Co | Anti-nkg2a antibodies and uses thereof |
| KR20210146349A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| JP2022527177A (ja) | 2019-03-28 | 2022-05-31 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| JP2022534981A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよび組み合わせ治療 |
| CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| EP3986454A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
| KR20220041079A (ko) | 2019-06-18 | 2022-03-31 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합 |
| TWI809286B (zh) | 2019-07-05 | 2023-07-21 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
| WO2021008559A1 (en) * | 2019-07-16 | 2021-01-21 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
| US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
| EP4031873A1 (en) | 2019-09-22 | 2022-07-27 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| CN114728070A (zh) | 2019-09-25 | 2022-07-08 | 百时美施贵宝公司 | 用于癌症疗法的复合生物标记物 |
| KR20220092578A (ko) | 2019-11-05 | 2022-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | M-단백질 검정 및 이의 용도 |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| KR20220093349A (ko) | 2019-11-08 | 2022-07-05 | 브리스톨-마이어스 스큅 컴퍼니 | 흑색종에 대한 lag-3 길항제 요법 |
| US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
| IL294085A (en) | 2019-12-19 | 2022-08-01 | Bristol Myers Squibb Co | Combinations of dgk inhibitors and checkpoint antagonists |
| CA3168923A1 (en) | 2020-01-30 | 2021-08-05 | ONA Therapeutics S.L. | Combination therapy for treatment of cancer and cancer metastasis |
| US20230087600A1 (en) | 2020-02-06 | 2023-03-23 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
| IL295979A (en) | 2020-03-06 | 2022-10-01 | Ona Therapeutics S L | Anti-cd36 antibodies and their use for cancer treatment |
| MX2022011701A (es) | 2020-03-23 | 2022-10-07 | Bristol Myers Squibb Co | Anticuerpos anti-receptor de quimiocina 8 con motivo c-c (ccr8) para el tratamiento del cancer. |
| BR112023003427A2 (pt) | 2020-08-28 | 2023-03-21 | Bristol Myers Squibb Co | Terapia com antagonista de lag-3 para carcinoma hepatocelular |
| MX2023002326A (es) | 2020-08-31 | 2023-03-21 | Bristol Myers Squibb Co | Firma de localizacion celular e inmunoterapia. |
| WO2022068919A1 (zh) * | 2020-09-30 | 2022-04-07 | 正大天晴康方(上海)生物医药科技有限公司 | 结合pd-1抗体的肽及其应用 |
| CN116406369A (zh) | 2020-10-05 | 2023-07-07 | 百时美施贵宝公司 | 用于浓缩蛋白质的方法 |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| WO2022094567A1 (en) | 2020-10-28 | 2022-05-05 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| CA3200671A1 (en) | 2020-11-17 | 2022-05-27 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| AU2021411486A1 (en) | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CA3206253A1 (en) * | 2021-02-04 | 2022-08-11 | Heung Rok Park | Anti-pd-1 antibody and use thereof |
| WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| CN118488964A (zh) | 2021-07-30 | 2024-08-13 | Ona疗法有限公司 | 抗cd36抗体及其治疗癌症的用途 |
| US20250002600A1 (en) | 2021-10-06 | 2025-01-02 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination therapy |
| MX2024005053A (es) | 2021-10-29 | 2024-05-10 | Bristol Myers Squibb Co | Terapia con antagonista del gen de activacion de linfocitos 3 (lag-3) para cancer hematologico. |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| CA3249004A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Polytherapy for Hepatocellular Carcinoma |
| MX2024010310A (es) | 2022-02-25 | 2024-08-28 | Bristol Myers Squibb Co | Terapia de combinacion para carcinoma colorrectal. |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| KR20250004645A (ko) | 2022-03-08 | 2025-01-08 | 알렌티스 테라퓨틱스 아게 | T 세포 가용성을 증가시키기 위한 항-클라우딘-1 항체의 사용 |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| IL315992A (en) | 2022-04-08 | 2024-11-01 | Bristol Myers Squibb Co | Identification, classification and quantification of tertiary lymphoid structures using machine learning |
| KR20250004779A (ko) | 2022-04-13 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암을 치료하기 위한 병용 요법 |
| WO2023205754A2 (en) * | 2022-04-20 | 2023-10-26 | University Of Utah Research Foundation | Antibodies specific to pd-1 and methods of use |
| JP2025516631A (ja) | 2022-05-12 | 2025-05-30 | ジェンマブ エー／エス | 併用療法においてｃｄ２７に結合する能力を有する結合剤 |
| US20250332252A1 (en) | 2022-06-02 | 2025-10-30 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN117229385A (zh) * | 2022-06-06 | 2023-12-15 | 北京卡替医疗技术有限公司 | Pd-1变体及其用途 |
| EP4310197A1 (en) | 2022-07-21 | 2024-01-24 | Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
| CN120379691A (zh) | 2022-09-30 | 2025-07-25 | 爱兰蒂斯疗法股份公司 | 耐药性肝细胞癌的治疗 |
| WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| EP4626552A1 (en) | 2022-12-01 | 2025-10-08 | MedImmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| AU2023409221A1 (en) | 2022-12-21 | 2025-06-12 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
| CN116077645A (zh) * | 2022-12-28 | 2023-05-09 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗非小细胞肺癌患者的药物中的用途 |
| WO2024150177A1 (en) | 2023-01-11 | 2024-07-18 | Advesya | Treatment methods for solid tumors |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| WO2024261239A1 (en) | 2023-06-23 | 2024-12-26 | Imcheck Therapeutics | Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| EP4658320A1 (en) | 2024-02-27 | 2025-12-10 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| JP4166691B2 (ja) | 2001-08-03 | 2008-10-15 | タイコ ヘルスケア グループ エルピー | 組織マーキング装置および方法 |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| WO2004056875A1 (en) * | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| CA2943949C (en) | 2004-10-06 | 2020-03-31 | Mayo Foundation For Medical Education And Research | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| BRPI0611766A2 (pt) | 2005-06-08 | 2011-12-20 | Dana Farber Cancer Inst Inc | métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| GB0614093D0 (en) | 2006-07-14 | 2006-08-23 | Bae Systems Plc | Deployable antenna system |
| CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| US8907065B2 (en) | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
| PT2336329E (pt) | 2007-06-01 | 2012-12-24 | Omt Inc | Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| JP5945096B2 (ja) * | 2008-07-04 | 2016-07-05 | 小野薬品工業株式会社 | 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用 |
| KR101721707B1 (ko) | 2008-11-28 | 2017-03-30 | 에모리 유니버시티 | 감염 및 종양 치료 방법 |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| CN101526890B (zh) | 2009-03-30 | 2011-01-05 | 昆山龙腾光电有限公司 | 显示拼接墙的显示单元的位置映射方法和装置 |
| CN101763842B (zh) | 2009-11-13 | 2012-07-11 | 广东威创视讯科技股份有限公司 | 拼接墙墙体的配置系统及其建立显示单元的位置映射方法 |
| CA2816225A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| CA2852474A1 (en) * | 2011-10-18 | 2013-04-25 | Emory University | Antibodies directed against influenza |
| JP2015135534A (ja) | 2012-05-09 | 2015-07-27 | パナソニック株式会社 | マルチ画面表示装置およびマルチ画面表示システム |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN107759686A (zh) * | 2012-05-30 | 2018-03-06 | 中外制药株式会社 | 靶组织特异性抗原结合分子 |
| CN102737616B (zh) | 2012-06-28 | 2015-07-08 | 广东威创视讯科技股份有限公司 | 大屏幕拼接墙单元位置自动识别方法及装置 |
| CN103242448B (zh) | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| US9676853B2 (en) * | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| CN103701643B (zh) | 2013-12-23 | 2017-06-13 | 广东威创视讯科技股份有限公司 | 获取拼墙系统配置的方法、装置及拼墙系统 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| KR20160119867A (ko) | 2014-03-05 | 2016-10-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료 |
| KR102870759B1 (ko) | 2014-05-15 | 2025-10-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료 |
| KR102360693B1 (ko) | 2014-07-11 | 2022-02-08 | 벤타나 메디컬 시스템즈, 인코포레이티드 | 항-pd-l1 항체 및 이의 진단 용도 |
| RU2726996C1 (ru) | 2014-12-16 | 2020-07-17 | Бристол-Маерс Сквибб Компани | Применение ингибиторов иммунных контрольных точек при новообразованиях центральной нервной системы |
| CN104479020B (zh) | 2014-12-26 | 2019-08-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗pd-1人源抗体 |
| BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| EP3265825A4 (en) | 2015-03-06 | 2018-08-08 | Dana-Farber Cancer Institute, Inc. | Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers |
| KR102740444B1 (ko) | 2015-04-17 | 2024-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| WO2016176503A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| WO2016176504A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| US20180155429A1 (en) | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| WO2016196389A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| DK3322731T3 (da) | 2015-07-14 | 2021-03-08 | Bristol Myers Squibb Co | Fremgangsmåde til behandling af cancer ved hjælp af immun checkpoint-hæmmer; antistof der binder til programmed death-1-receptor (pd-1) eller programmed death ligand-1 (pd-l1) |
| CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| UA124379C2 (uk) | 2015-08-11 | 2021-09-08 | Усі Байолоджікс Айрленд Лімітед | Нові антитіла проти білка pd-1 |
| SG10201912943RA (en) | 2015-10-02 | 2020-02-27 | Symphogen As | Anti-pd-1 antibodies and compositions |
| CN105336289A (zh) | 2015-10-30 | 2016-02-17 | 京东方科技集团股份有限公司 | 一种拼接控制方法、装置以及拼接屏系统 |
| CN205017477U (zh) | 2015-10-30 | 2016-02-03 | 京东方科技集团股份有限公司 | 一种拼接控制装置以及拼接屏系统 |
| CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| WO2017132508A1 (en) | 2016-01-27 | 2017-08-03 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| US11209441B2 (en) | 2016-04-05 | 2021-12-28 | Bristol-Myers Squibb Company | Cytokine profiling analysis |
| DK3463457T3 (da) | 2016-06-02 | 2023-10-02 | Bristol Myers Squibb Co | Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom |
| WO2017210637A1 (en) | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
| WO2017210624A1 (en) | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treating a tumor |
| RU2757316C2 (ru) | 2016-09-21 | 2021-10-13 | СиСТОНЕ ФАРМАСЬЮТИКАЛС | Новые моноклональные антитела к белку программируемой смерти 1(pd-1) |
| KR20240019398A (ko) | 2016-10-28 | 2024-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법 |
| CA3043141A1 (en) | 2016-11-18 | 2018-05-24 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
| WO2018132287A1 (en) | 2017-01-11 | 2018-07-19 | Dana-Farber Cancer Institute, Inc. | Pbrm1 biomarkers predictive of anti-immune checkpoint response |
| EP3585812A1 (en) | 2017-02-21 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Anti-pd-1 antibodies for treatment of lung cancer |
| US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7780857B2 (ja) | 2017-06-01 | 2025-12-05 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| US11899017B2 (en) | 2017-07-28 | 2024-02-13 | Bristol-Myers Squibb Company | Predictive peripheral blood biomarker for checkpoint inhibitors |
| CN109575140B (zh) | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| CN109721657B (zh) | 2017-10-27 | 2021-11-02 | 北京比洋生物技术有限公司 | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 |
-
2016
- 2016-08-11 UA UAA201802340A patent/UA124379C2/uk unknown
- 2016-08-11 KR KR1020177036687A patent/KR102055396B1/ko active Active
- 2016-08-11 MY MYPI2018700283A patent/MY187739A/en unknown
- 2016-08-11 MX MX2018001644A patent/MX392711B/es unknown
- 2016-08-11 IL IL293385A patent/IL293385B1/en unknown
- 2016-08-11 HU HUE16834675A patent/HUE068751T2/hu unknown
- 2016-08-11 HR HRP20241381TT patent/HRP20241381T1/hr unknown
- 2016-08-11 PE PE2018000225A patent/PE20181018A1/es unknown
- 2016-08-11 US US15/751,236 patent/US11008391B2/en active Active
- 2016-08-11 WO PCT/CN2016/094624 patent/WO2017025051A1/en not_active Ceased
- 2016-08-11 LT LTEPPCT/CN2016/094624T patent/LT3334763T/lt unknown
- 2016-08-11 RU RU2020124273A patent/RU2020124273A/ru unknown
- 2016-08-11 IL IL257062A patent/IL257062B/en unknown
- 2016-08-11 ES ES16834675T patent/ES2992478T3/es active Active
- 2016-08-11 EA EA201890468A patent/EA201890468A1/ru unknown
- 2016-08-11 SI SI201631856T patent/SI3334763T1/sl unknown
- 2016-08-11 PL PL16834675.7T patent/PL3334763T3/pl unknown
- 2016-08-11 DK DK16834675.7T patent/DK3334763T3/da active
- 2016-08-11 EP EP16834675.7A patent/EP3334763B1/en active Active
- 2016-08-11 RU RU2018108048A patent/RU2729830C2/ru active
- 2016-08-11 MA MA042626A patent/MA42626A/fr unknown
- 2016-08-11 IL IL322492A patent/IL322492A/en unknown
- 2016-08-11 PT PT168346757T patent/PT3334763T/pt unknown
- 2016-08-11 SG SG10201914109VA patent/SG10201914109VA/en unknown
- 2016-08-11 AU AU2016305697A patent/AU2016305697B2/en active Active
- 2016-08-11 CA CA2993276A patent/CA2993276A1/en active Pending
- 2016-08-11 EP EP24191585.9A patent/EP4458417A3/en active Pending
- 2016-08-11 FI FIEP16834675.7T patent/FI3334763T3/fi active
- 2016-08-11 JP JP2018526985A patent/JP6883579B2/ja active Active
-
2018
- 2018-01-24 PH PH12018500183A patent/PH12018500183A1/en unknown
- 2018-01-30 CO CONC2018/0000992A patent/CO2018000992A2/es unknown
- 2018-02-08 MX MX2022006447A patent/MX2022006447A/es unknown
- 2018-02-09 CL CL2018000370A patent/CL2018000370A1/es unknown
- 2018-02-11 SA SA521422116A patent/SA521422116B1/ar unknown
- 2018-02-11 SA SA518390903A patent/SA518390903B1/ar unknown
- 2018-03-09 EC ECIEPI201818842A patent/ECSP18018842A/es unknown
-
2020
- 2020-12-02 JP JP2020200034A patent/JP2021036914A/ja not_active Withdrawn
-
2021
- 2021-04-26 US US17/239,866 patent/US11643465B2/en active Active
-
2022
- 2022-08-22 JP JP2022131714A patent/JP2022161997A/ja active Pending
-
2023
- 2023-02-16 AU AU2023200891A patent/AU2023200891B2/en active Active
- 2023-03-20 US US18/186,793 patent/US20230348602A1/en not_active Abandoned
-
2025
- 2025-01-31 JP JP2025014891A patent/JP2025081352A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500002I1 (hu) | Újszerû anti-PD-L1 antitestek | |
| IL282403B1 (en) | Antibodies against pd-1 | |
| IL257062A (en) | New anti-pd-1 antibodies | |
| HUS2500024I1 (hu) | ANTI-PD-1 ellenanyagok | |
| IL255727A (en) | Novel anti-pd-l1 antibodies | |
| SI3512547T1 (sl) | Anti-PD-1 protitelesa | |
| IL251963A0 (en) | Anti-1-pd antibodies | |
| IL250415A0 (en) | Antibodies against pd-l1 | |
| SG11201705552QA (en) | Anti-pd-l1 antibodies | |
| GB201521391D0 (en) | Antibodies | |
| GB201521382D0 (en) | Antibodies | |
| GB201508180D0 (en) | Antibodies | |
| GB201509907D0 (en) | Antibodies | |
| GB201503438D0 (en) | Antibodies | |
| GB201419080D0 (en) | Anti-PD-1 antibodies | |
| GB201419087D0 (en) | Anti-PD-1 antibodies | |
| GB201518728D0 (en) | Antibodies | |
| GB201515572D0 (en) | Anti-LAG-3 antibodies | |
| GB201515570D0 (en) | Anti-LAG-3 antibodies | |
| GB201514425D0 (en) | Antibodies | |
| GB201508437D0 (en) | Antibodies | |
| GB201508444D0 (en) | Antibodies | |
| GB201507541D0 (en) | Antibodies | |
| GB201504858D0 (en) | Antibodies | |
| GB201502591D0 (en) | Antibodies |